



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Troglitazone (Standard)

Cat. No.:	HY-50935R
CAS No.:	97322-87-7
Molecular Formula:	C ₂₄ H ₂₇ NO ₅ S
Molecular Weight:	441.54
Target:	Apoptosis; PPAR; Autophagy; Ferroptosis
Pathway:	Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Troglitazone (Standard) is the analytical standard of Troglitazone. This product is intended for research and analytical applications. Troglitazone is an orally active PPAR γ agonist, with EC₅₀s of 550 nM and 780 nM for human and murine PPAR γ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.

IC₅₀ & Target

EC₅₀: 550 nM (Human PPAR γ), 780 nM (Murine PPAR γ)^[1]

REFERENCES

- [1]. Willson TM, et al. The PPARs: from orphan receptors to drug discovery. *J Med Chem.* 2000 Feb 24;43(4):527-50.
- [2]. Fujita M, et al. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. *J Exp Clin Cancer Res.* 2017 Jul 3;36(1):91.
- [3]. Nazim UM, et al. PPAR γ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. *Oncotarget.* 2017 Apr 18;8(16):26819-26831.
- [4]. Knowler WC, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. *Diabetes.* 2005 Apr;54(4):1150-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA